PerkinElmer expands in vivo instruments portfolio  

PerkinElmer has expanded its in vivo imaging portfolio with the launch of the Vega imaging system, an ultrasound platform that combines hands-free, automated technology with high-throughput capability to accelerate non-invasive research and drug development studies of cancer, liver and kidney disease, cardiology and more.  

The Vega system  

The system eliminates challenges associated with conventional hand-held ultrasound systems through the use of two automated transducers located below the imaging stage. This design results in easy-to-use technology which can be operated without a dedicated sonographer, while producing more consistent results compared to traditional ultrasound systems.  

The Vega system’s high-throughput capability allows researchers to sequential scan up to three subjects in just a few minutes. Additionally, widefield imaging enables researchers to visualise pathophysiology of disease or effects of therapies within the broader anatomical and pathological context. 

Official comments 

“We’re pleased to offer researchers the innovative Vega ultrasound system to help R&D productivity with rapid image acquisition supporting a range of ultrasound studies while meeting increasing demand for non-invasive animal imaging technologies,” said Alan Fletcher, Senior Vice President of Life Science at PerkinElmer. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free